Loading...
Primary tumors of the central nervous system in Mongolia
Зохиогч
Orkhontuul Shirmen
Khusayan Khairulla
Avaajigmed Lkhamjav
Tsetsegdelger Munkhjarzgal
Он
2019 оны есдүгээр сарын 1
Төрөл
journal article
Хэвлэгч
Elsevier BV
Journal
IBRO Reports
Volume
6
Start Page
S234
End Page
S235
ISSN
2451-8301
Хураангуй
Fetal exposure to maternal stress can directly or indirectly influence offspring neurodevelopment and predispose to mental disorders on a later stage.The aim of the present study was to explore the curative effects of the melatoninergic drug Piromelatine on anxiety disorders in offspring with a history of prenatal stress (PNS).Pregnant rats, Sprague Dawley strain, were left undisturbed until the 7th gestation day.Then, the rats were exposed to different stress factors until the 21st day/birth.Chronic treatment with the melatonin compound Piromelatine (20 mg/kg), or vehicle for the matched controls, was injected intraperitoneally for 21 days and began when the male offspring reached sexual maturity (60 days).Several experimental tests were carried out on male offspring during the treatment period for the assessment of the anxiety-like behavior: Elevated plus maze (EPM), Open field (OF) and Light/Dark Test (LDT).Prenatal stress decreased the motor activity of the offspring, indicated in both tests the OF and the EPM.Prenatally stressed offspring showed reduced time spent in the aversive central area of the OF and in the open arms of the EPM, and demonstrated higher anxiety index compared to the controls.In the LDT, rats exposed to prenatal maternal stress were characterized with decreased number of crossings and time spent into the light area.Chronic treatment with the antidepressant Piromelatine corrected the negative impact of the PNS and abolished the anxiety-like behavior.Current investigational results suggest Piromelatine as a potential therapeutic candidate against anxiety-related behavior caused by prenatal stress.